PVX108: A next generation immunotherapy for the treatment of peanut allergy
PVX108 utilises peptides that represent carefully selected fragments of peanut proteins to switch off allergic reactions to peanuts. Unlike other peanut allergy immunotherapies under development, the peptides do not contain the parts of the peanut proteins that cause life-threatening anaphylactic reactions.
Scientific research shows that when peptides interact with immune cells in the absence of simultaneous inflammation, the immune cells that cause allergy can be reprogrammed to become tolerant.
Aravax is developing PVX108 as a simple monthly intra-dermal injection to induce tolerance to peanuts and reduce the risk of severe allergic reactions upon accidental exposure.
PVX108 is therefore set apart from other peanut allergy products in development as:
It targets the underlying cause of disease
It is designed to remove the risk of acute reactions to therapy
It does not require careful dose escalation
The technology underpinning PVX108 was developed by Professor Robyn O’Hehir, Professor Jennifer Rolland and Dr Sara Prickett at Alfred Health and Monash University, in Melbourne Australia. As co-inventors of PVX108 they played a significant role in the foundation of Aravax Pty Ltd.
We are grateful to the Australian Food Allergy Foundation, the Alfred Hospital Trust, and the National Health and Medical Research Council for their support of the early research that has created this exciting opportunity to revolutionise the treatment of peanut allergy.